Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Invested Capital (2019 - 2025)

Vivos Therapeutics' Invested Capital history spans 7 years, with the latest figure at -$1.3 million for Q4 2025.

  • Quarterly results put Invested Capital at -$1.3 million for Q4 2025, down 116.62% from a year ago — trailing twelve months through Dec 2025 was -$1.3 million (down 116.62% YoY), and the annual figure for FY2025 was -$1.3 million, down 116.62%.
  • Invested Capital for Q4 2025 was -$1.3 million at Vivos Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $37.7 million in Q2 2021 to a low of -$1.3 million in Q4 2025.
  • The 5-year median for Invested Capital is $6.7 million (2023), against an average of $10.4 million.
  • The sharpest move saw Invested Capital surged 16563.04% in 2024, then tumbled 116.62% in 2025.
  • Year by year, Invested Capital stood at $26.8 million in 2021, then crashed by 82.09% to $4.8 million in 2022, then plummeted by 91.44% to $411000.0 in 2023, then surged by 1835.28% to $8.0 million in 2024, then tumbled by 116.62% to -$1.3 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at -$1.3 million, $2.9 million, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.